Origin of brain tumors: historical insights
===========================================

Over a century ago, the German pathologist Julius Cohnheim described the similarities between tumors and embryonic cells and suggested that "embryonic rests" were the source of tumors ([@b41-sccaa-1-41]). Later, the primitive cytoarchitecture and embryonic features of many malignant brain tumors was also described by [@b4-sccaa-1-41]. [@b50-sccaa-1-41] observed that "subependymal glia may actually be the point of origin of tumors of the thalamus."

These earlier descriptions were further advanced in 1944, Joseph Globus and Hartwig Kuhlenbeck called attention to the subependymal cell plate in the adult brain and described this structure as one with primitive cellular composition. Based on a study with human brain tumors, they stated that "one of the most important sources for such immature embryonal residue from which neuroectodermal tumors are likely to develop under certain still unknown conditions is the subependymal plate." ([@b19-sccaa-1-41]).

The subependymal plate was better characterized as a "mitotically active and well defined subependymal layer is present in mammalian brains throughout life" and [@b32-sccaa-1-41] suggested that they could be a "possible source of different histological varieties of glioma, in particular those tumors in paraventricular situation and butterfly gliomas of the corpus callosum."

In the late 1960s [@b23-sccaa-1-41] demonstrated increased glial tumors with periventricular implantation of carcinogens in rats. In the 1970s, periventricular tumors were then demonstrated to occur in the subventricular region after intraventricular inoculation with avian sarcoma viruses, with a much higher rate of tumors occurring in neonatal rats versus adult rats ([@b12-sccaa-1-41]; [@b11-sccaa-1-41]; [@b57-sccaa-1-41]). A single dose of ethylnitrosurea administration to pregnant rats also induced periventricular tumors in the offspring ([@b27-sccaa-1-41]).

Now clear evidence exists for the "subependymal plate, as described by Gobus and Kuhlenbeck is the subventricular zone (SVZ), know to be the largest cellular region of neural stem cells (NSCs) in the adult mammalian brain. The NSCs have been characterized by Buyalla and provide the migratory neuroblasts for neurogeneis in the olfactory bulb in rodents ([Figure 1](#f1-sccaa-1-41){ref-type="fig"}) ([@b45-sccaa-1-41]). Recently, this migratory path for SVZ NSCs was also described in humans ([@b13-sccaa-1-41]).

Reappraising the prevailing theory of tumor genesis
===================================================

It has been widely accepted that cancer occurs as a consequence of genetic and epigenetic alterations in a differentiated cell. These alterations could provide a proliferative advantage and ultimately lead to uncontrolled growth and spread of the malignant cells. This theory suggests that tumors, such as gliomas, result from mutations to terminally differentiated astrocytes and oligodendrocytes that "de-differentiate" into a less differentiated phenotype ([@b34-sccaa-1-41]; [@b17-sccaa-1-41]; [@b44-sccaa-1-41]). Although the neoplastic transformation of fully differentiated glia is widely assumed to be the mechanism of gliomagenesis, this hypothesis has never been adequately tested.

Evidence for NSC as the cell of origin
======================================

The neurogenic zones within the human central nervous system (CNS) with their resident NSCs are considered the leading candidates for transformation leading to brain tumors. Specifically mitotically active cells (NSCs and their direct progeny, transit amplifying cells) are the cells that have the greatest probability of being the brain tumor cell of origin.

NSCs and gliomas share histological and biological similarities
---------------------------------------------------------------

Gliomas have long been described by pathologists for their remarkable cellular heterogeneity, and in fact the most aggressive and malignant glioma (glioblastoma multiforme) was termed based partly on the histological diversity comprising this tumor, hence "multiform." A transformed NSC could provide this cellular landscape due to their mulitipotentiallity (ability to differentiate into the cell types that constitute their respective germ line). Mixed cell gliomas exist, such as oligoastrocytomas, and have both oligodendrocytes and astrocytes ([@b54-sccaa-1-41]) and could be independent transformation of two differentiated cells, as suggested by the dedifferentiation theory of tumor genesis. More plausible would be the transformation of a single, bipotential progenitor cell such as a NSC or a transit amplifying cell ([@b8-sccaa-1-41]). These mixed cell gliomas also exhibit loss of heterozygosity on chromosomes 1p and 19q in both the astrocytic and oligodendrocytic components ([@b28-sccaa-1-41]), suggesting that, in oligoastrocytomas, the astrocytes and oligodendrocytes comprising the tumor have a shared cell of origin.

Further, many glioma cells are undifferentiated, and lack expression of differentiated cell markers, as well as demonstrate staining with markers for nestin. Nestin expression is one hallmark feature of NSCs ([@b14-sccaa-1-41]; [@b52-sccaa-1-41]), and has become a reliable marker of NSCs ([@b31-sccaa-1-41]). Gliomas and NSCs also exhibit characteristic overlapping behavior ([Table 1](#t1-sccaa-1-41){ref-type="table"}) ([@b45-sccaa-1-41]), such as high motility, association with vasculature and white matter tracts ([@b48-sccaa-1-41]; [@b18-sccaa-1-41]; [@b38-sccaa-1-41]).

NSCs more likely to accumulate oncogenic mutations
--------------------------------------------------

Accumulation of oncogenic genetic hits by cells is an infrequent stochastic event that most likely takes considerable time to result in transformation. NSCs, defined by their ability to self renew are both mitotically active and exist during the lifetime of the animal, allowing them to potentially accumulate the necessary multiple mutations for tumor formation. Accordingly, the cellular origin of gliomas would most likely occur from the proliferative zones in the mammalian CNS such as the SVZ contain at least two types of mitotically active cells: NSCs and transit amplifying cells (TACs) ([@b46-sccaa-1-41]). Although TACs exist only briefly and then differentiate, their total cellular compartment is significantly larger than NSCs and total number of global number of divisions during their relatively short lifespan are comparable to NSCs that exist throughout life yet are less mitotically active ([Figure 2](#f2-sccaa-1-41){ref-type="fig"}) ([@b55-sccaa-1-41]).

Cancer stem cells
-----------------

Approximately 150 years ago, pathologists Rudolph Virchow and Julius Cohnheim suggested there were histological similarities between the developing fetus and certain cancers (such as teratocarcinomas) and that both tissues have the capacity to differentiate and proliferate. This "embryonal-rest hypothesis" is the historical version of today's cancer stem cell (CSC) hypothesis ([@b24-sccaa-1-41]). As defined at the American Association for Cancer Research workshop on cancer stem cells: cancer stem cells are cells that (1) self renew and (2) re-supply the tumor with the various lineages of cells of which it is comprised. Self renewal can only be defined experimentally by the ability to recapitulate the generation of a continuously growing tumor or tumor initiation cell ([Figure 3](#f3-sccaa-1-41){ref-type="fig"}) ([@b10-sccaa-1-41]; [@b30-sccaa-1-41]).

The original work establishing the CSC model was based on the hematopoietic system. Evidence for leukemia-CSCs was first reported in 1994 when Lapidot and colleagues isolated a rare population of CD34+CD38− cells from patients with acute myeloid leukemia. Infusion of these CD34+CD38− cells into severe combined immune-deficient mice resulted in leukemic blast generation; however, more differentiated cells (CD34+ CD38+) did not generate leukemia ([@b29-sccaa-1-41]; [@b1-sccaa-1-41]; [@b7-sccaa-1-41]). On a molecular level, CSCs share properties with normal stem cells. They have similar markers and signaling pathways, respond to environmental cues, as well as telomerase activity, apoptosis clearance and increased membrane transporter activity ([@b44-sccaa-1-41]).

The first report of cells with stem-like properties in brain tumors was by [@b25-sccaa-1-41] where surgical specimens of glioblastoma multiforme were shown to have clonogenic neurosphere-forming cells that expressed both neuronal and glial markers upon differentiation ([Figure 4](#f4-sccaa-1-41){ref-type="fig"}) ([@b25-sccaa-1-41]; [@b55-sccaa-1-41]). Subsequently, the Dirks group demonstrated CSC in brain tumors by 1 transplantation of CD133+ or CD133− populations into immunodeficient mice. With as few as 100 CD133+ cells from the primary tumor, a new phenocopy of the tumor could be created in the transplanted mice; and unsorted or CD133− primary tumor cells were unable to cause de novo tumor generation. As part of what has come to define CSCs-self-renewal capacity -- was also shown by confirming the ability of serially transplanted CD133+ cells to recapitulate the original tumor ([@b49-sccaa-1-41]; [@b7-sccaa-1-41]). These findings established the presence of brain tumor stem cells (BTSCs), cells which can differentiate into the neural lineages, and exhibit self renewal as demonstrated by recapitulation of primary tumors with serial transplantation. This has been shown for other types of brain tumors as well ([@b36-sccaa-1-41]; [@b51-sccaa-1-41]). The existence of these BTSCs adds further evidence toward the NSCs origin of gliomas by confirming that different brain tumors contain transformed, undifferentiated neural precursors that respond to the same mitogens that activate adult NSCs ([@b55-sccaa-1-41]). Second, they indicate that tumor stem-like cells possess some of the molecular features of NSCs. Third, BTSCs, through asymmetric division, could generate a BTSCs and a progenitor cell, the latter of which may migrate away to either form or contribute to the tumor mass ([@b55-sccaa-1-41], [@b6-sccaa-1-41]).

Gliomas and NSCs have common regulatory pathways
------------------------------------------------

Neural stem cells and progenitor cells have activated cellular pathways, such as pro-mitotic genes, telomerase activity, and anti-apoptotic genes. This innate capacity overlaps with the mechanisms underlying tumor initiation, progression, or both. Thus, NSCs may require the least amount of mutations to become transformed.

1.  EGFR expression is up-regulated in primary glioblastoma multiforme and transiently dividing progenitors (type C cells) ([@b35-sccaa-1-41]).

2.  Fibroblast growth factors (FGFs) are involved in tumor proliferation and angiogenesis ([@b26-sccaa-1-41]; [@b2-sccaa-1-41]) and also shown to regulate NSC proliferation and cell fate ([@b56-sccaa-1-41]; [@b20-sccaa-1-41]; [@b37-sccaa-1-41]).

3.  Notch receptors and signaling is involved in NSC renewal ([@b22-sccaa-1-41]; [@b47-sccaa-1-41]) and related to proliferative capacity of gliomas ([@b39-sccaa-1-41]).

4.  PTEN is a tumor suppressor with an important function in the control of proliferation of neural stem cells and progenitor cells in vivo and in vitro ([@b5-sccaa-1-41]; [@b21-sccaa-1-41]; [@b42-sccaa-1-41]). *PTEN* is inactivated in glioblastomas ([@b40-sccaa-1-41]; [@b58-sccaa-1-41]) and its preservation in glioblastoma multiforme is clinically favorable ([@b35-sccaa-1-41]).

5.  The Wnt-catenin pathway regulates adult neurogenesis ([@b9-sccaa-1-41]; [@b33-sccaa-1-41]) modulating its activity may increase glioma cell growth ([@b43-sccaa-1-41]).

Recent experiments have also highlighted the increased ability of progenitor cells to be transformed versus differentiated cell types. If epidermal growth factor receptor (EGFR) is transfected into transgenic *Ink4a-Arf-/-* mouse (lacking genes for cell-cycle arrest) neural stem cells, the cells lead to glioma formation ([@b3-sccaa-1-41]). This contrasted with similar manipulation of differentiated mouse astrocytes. Further, if the undifferentiated mouse astrocytes were transfected with platelet-derived growth factor (*pdgf*) transgene and converted to a less differentiated state, they showed increased oncogenicity ([@b15-sccaa-1-41]; [@b3-sccaa-1-41]; [@b53-sccaa-1-41]).

Mouse models of gliomas for investigation of glioma origin
----------------------------------------------------------

Mouse models of gliomas are available and offer a unique opportunity to investigate tumor origin. These models, unlike glioma models in *Drosophila* and *C. elegans*, recapitulate the human pathology in terms of such characteristic structures as pleomorphic nuclei, diffusely infiltrative margins, secondary structures of Scherer, necrosis with pseudopalisading tumor cells, and microvascular proliferation. Xenograft models fail to phenocopy the classic histopathological features and are not an option for elucidating developmental mechanisms. Ultimately, these models of spontaneous tumor development and progression allows for the potential identification of novel mechanisms for tumorigenesis ([@b16-sccaa-1-41]).

Relevance of identifying the glioma cell of origin
--------------------------------------------------

Brain tumor classification with current histological criteria fails to accurately categorize patients as many patients with similar grade brain tumors have highly variable clinical outcomes. Clearly, this classification is one that at a minimum needs molecular modifiers. Defining the cell of origin, and confirming whether NSCs are indeed the cell of origin would improve not only glioma classifications, but also detection and treatment. The differential antigenic and molecular attributes of NSCs responsible for tumorigenesis could be exploited to target malignant cells prior tumor progression to clinical presentation. Indeed, defining cell of origin could help expand the concept of chemoprevention: targeting cells in the pre-morbid state.
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![The cells of the subventricular zone, labeled with the astrocyte marker GFAP (shown in green), line the lateral walls of the lateral ventricles. This is the largest known region of adult neural stem cells in the human brain; it is composed of the deep subcortical white matter **A**), a periventricular ribbon of astrocytes that can function as neural stem cells **B**), a dense layer of astrocytic processes **C**), and the ependymal lining **D**). Throughout adult life, astrocytes from the subventricular zone exhibit a unique capacity for multipotency and self-renewal in vitro. Copyright © 2005. Reproduced with permission from [@b45-sccaa-1-41]. Neural stem cells and the origin of gliomas. *N Engl J Med*, 353:811--22.](sccaa-1-41f1){#f1-sccaa-1-41}

![Hierarchical organization of the functional compartments in renewing tissues **A**) The stem-cell compartment (purple), early transiently dividing progenitor compartment (orange), late transiently dividing progenitor compartment (red) and differentiated-cell compartment (green) are schematically described. Cells in the stem-cell and transiently dividing progenitor compartments could be the target of the onco-transformation that leads to the formation of tumour stem cells **B**) The neural precursors that make up similar functional compartments in the neurogenetic regions of the adult brain and that might be the source of brain tumour stem cells **C**) The structure of the subventricular zone, showing how these precursors fit and are organized in the germinal neuroepithelium of the largest neurogenetic region of the adult brain.\
**Abbreviations:** GABA, γ-aminobutyric acid; GFAP, glial fibrillary acid protein; HSA, heat-stable antigen; MAP2, microtubule-associated protein 2; NCAM1, neural cell adhesion molecule 1; PSA, polysialic acid; RMS, rostral migratory stream.](sccaa-1-41f2){#f2-sccaa-1-41}

![Overview of tumor stem cells in cancer. Cancer stem cells (tumor-initiating cells) divide asymmetrically, resulting in self-renewal of the tumor-initiating cell and production of a daughter cell known as a transient-amplifying cell (progenitor cell). The transient-amplifying cell is not thought to possess self-renewing capabilities, but instead divides indefinitely to contribute to cancer progression. Copyright © 2007. Reproduced with permission from [@b30-sccaa-1-41]. Old disease, new culprit: tumor stem cells in cancer. *J Cell Physiol*, 213:603--9.](sccaa-1-41f3){#f3-sccaa-1-41}

![Immunofluorescence photomicrographs of representative MC-PL clones derived from different cortical glial tumor specimens (T1--T3, T6, and T7) processed for double (**A**, **B**, **C**, **E**, **F**) or single (**B** inset, **D**) labeling for different neural markers. The cells positive for the neuronal marker β-III tubulin are stained green (FITC), and the cells that expressed the astroglial marker GFAP are stained blue (AMCA). The arrowhead in F points out a cell that is not labeled for GFAP, but is immunopositive for β-III tubulin (arrowhead in **G**). The short arrow in **F** points out a cell that is immunolabeled for GFAP, but immunonegative for β-III tubulin (short arrow in **G**). The long arrow in **F** and **G** points out a cell that is labeled with both immunomarkers. Scale bars are 10 μm (**F** and **G**) and 100 μm (**A**--**E**). Copyright © 2002. [@b25-sccaa-1-41]. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. *Glia*, 39:193--206.](sccaa-1-41f4){#f4-sccaa-1-41}

###### 

Characteristics intrinsic to neural stem cells and gliomas. Copyright © 2005. Reproduced with permission from [@b45-sccaa-1-41]. Neural stem cells and the origin of gliomas. *N Engl J Med*, 353:811--22

  --------------------------------------
  High motility
  Diversity of progeny
  Robust proliferative potential
  Association with blood vessels
  Association with white-matter tracts
  Immature expression profiles
    Nestin expression
    EGF-receptor expression
    PTEN expression
    Hedgehog pathway activity
    Telomerase activity
    Wnt pathway activity
  --------------------------------------

**Abbreviation:** EGF, epidermal growth factor.
